教育经历
1.2011.09-2015.06，上海中医药大学，中药学
2.2016.08-2018.06，澳门大学，医药管理
3.2019.01-2022.09，澳门大学，生物医药（医药管理方向）
科研与学术经历
1. 2020.08-2021.08，英国埃塞克斯大学，访问学生
2. 2022.12-至今，东南大学，公共卫生学院，讲师
研究方向
1. 卫生经济学评价
2. 医疗卫生保障系统与政策研究
3.真实世界研究
主持或参加科研项目（课题）情况
1. 北京健康促进会：气候医疗产业研究（2020）
2. 中国食品药品国际交流中心：真实世界证据开发趋势和政策应用的国际比较研究（2019）
3.中国药品监督管理研究会：监管科学实施现况及发展趋势:国际比较研究（2019）
代表性研究成果和学术奖励情况
1. Li M, Chen S, Zhao H, Tang C, Lai Y, Ung CO, Su J, Hu H. The short-term associations of chronic obstructive pulmonary disease hospitalizations with meteorological factors and air pollutants in Southwest China: a time-series study. Scientific reports. 2021;11(1):1-0.
2. Li M, Cheng K, Ku K, Li J, Hu H, Ung CO. Factors Influencing the Length of Hospital Stay Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in Macao Population: A Retrospective Study of Inpatient Health Record. International Journal of Chronic Obstructive Pulmonary Disease. 2021;16:1677.
3. Li M, Chen S, Lai Y, Liang Z, Wang J, Shi J, Lin H, Yao D, Hu H, Ung CO. Integrating real-world evidence in the regulatory decision-making process: a systematic analysis of experiences in the US, EU, and China using a logic model. Frontiers in medicine. 2021; 8:778.
4. Li M, Wang F, Chen R, Liang Z, Zhou Y, Yang Y, Chen S, Ung CO, Hu H. Factors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record data. International Journal of Chronic Obstructive Pulmonary Disease. 2018;13:3349.
5. Zou H, Li M, Lei Q, Luo Z, Xue Y, Yao D, Lai Y, Ung CO, Hu H. Economic burden and quality of life of hepatocellular carcinoma in greater China: a systematic review. Frontiers in public health. 2022; 21:767.
6. Tang D, Li M, Ung CO, Tang C, Hu H. Exploratory study on development challenges of maternal and child healthcare institutions in China: a qualitative study combining interviews and focus groups. BMJ open. 2019; 9(6):e028789.
7. Liang Z, Lai Y, Li M, Shi J, Lei CI, Hu H, Ung CO. Applying regulatory science in traditional chinese medicines for improving public safety and facilitating innovation in China: a scoping review and regulatory implications. Chinese medicine. 2021;16(1):1-6.
8. Lai Y, Chen S, Li M, Ung CO, Hu H. Policy interventions, development trends, and service innovations of internet hospitals in China: documentary analysis and qualitative interview study. Journal of medical Internet research. 2021;23(7):e22330.
9. Suo S, Lai Y, Li M, Song Q, Cai J, Zhao J, Yang Q, Ung CO, Hu H. Phytochemicals, pharmacology, clinical application, patents, and products of Amomi fructus. Food and Chemical Toxicology. 2018;119:31-6.
10. Shi H, Guo W, Zhu H, Li M, Ung CO, Hu H, Han S. Cost-effectiveness analysis of xiyanping injection (andrographolide sulfonate) for treatment of adult community acquired pneumonia: a retrospective, propensity score-matched cohort study. Evidence-Based Complementary and Alternative Medicine. 2019.
11. Chen W, Li X, Chen Z, Hao W, Yao P, Li M, Liu K, Hu H, Wang S, Wang Y. A comprehensive quality analysis of randomized controlled clinical trials of Asian ginseng and American ginseng based on the CONSORT guideline. Journal of ginseng research. 2022;46(1):71-8.
12.李蒙, 胡豪, & 吴霭琳. (2020). 大数据在药物警戒中的应用研究进展. 中国药物警戒, 17(5), 311.